0001640455-21-000021.txt : 20210125 0001640455-21-000021.hdr.sgml : 20210125 20210125173658 ACCESSION NUMBER: 0001640455-21-000021 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210122 FILED AS OF DATE: 20210125 DATE AS OF CHANGE: 20210125 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cole Hugh M CENTRAL INDEX KEY: 0001604646 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37998 FILM NUMBER: 21550943 MAIL ADDRESS: STREET 1: C/O ARIAD PHARMACEUTICALS, INC STREET 2: 26 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Jounce Therapeutics, Inc. CENTRAL INDEX KEY: 0001640455 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 454870634 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 780 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-259-3840 MAIL ADDRESS: STREET 1: 780 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 wf-form4_161161420401615.xml FORM 4 X0306 4 2021-01-22 0 0001640455 Jounce Therapeutics, Inc. JNCE 0001604646 Cole Hugh M C/O JOUNCE THERAPEUTICS, INC. 780 MEMORIAL DRIVE CAMBRIDGE MA 02139 0 1 0 0 Chief Business Officer Common Stock 2021-01-22 4 M 0 5000 4.40 A 60189 D Common Stock 2021-01-22 4 M 0 5000 6.55 A 65189 D Common Stock 2021-01-22 4 S 0 18000 11.95 D 47189 D Stock Option (Right to Buy) 4.4 2021-01-22 4 M 0 5000 0 D 2029-02-01 Common Stock 5000.0 39500 D Stock Option (Right to Buy) 6.55 2021-01-22 4 M 0 5000 0 D 2030-02-03 Common Stock 5000.0 55000 D The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 22, 2020. The Reporting Person exercised no discretion with respect to these transactions. Represents the weighted average share price of an aggregate total of 18,000 shares sold in the price range of $11.66 to $12.24 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. The option will vest quarterly in 16 equal installments following January 1, 2019. The option will vest quarterly in 16 equal installments following January 1, 2020. /s/ Caroline Gammill, Attorney-in-fact 2021-01-25